{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-017199","form_type":"8-K","ticker":"HSIC","cik":"0001000228","company_name":"HENRY SCHEIN INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.112078+00:00","generated_at":"2026-05-22T16:00:59.415385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Henry Schein Q1 GAAP EPS $0.88 (+22% YoY); non-GAAP EPS $1.15 (+4.5%); maintains FY guidance","bullets":["Q1 net sales $3.2B; constant currency sales up 1.4% (2.0% ex-PPE/COVID test kits).","Global Distribution sales +0.8% constant currency; Medical +3.0%, Specialty +4.3%.","Repurchased $161M of stock (~2.3M shares at avg $71.58); $718M remaining authorization.","Restructuring costs $25M in Q1; expects annual run-rate savings at high end of $75M-$100M by end-2025.","FY2025 guidance unchanged: non-GAAP EPS $4.80-$4.94, sales growth 2%-4%, mid-single digit EBITDA growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-017199","json":"https://secwatch.observer/filing/0001140361-25-017199.json","markdown":"https://secwatch.observer/filing/0001140361-25-017199.md","text":"https://secwatch.observer/filing/0001140361-25-017199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000228/000114036125017199/0001140361-25-017199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000228/000114036125017199/hsic-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:00:59.415385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}